Trial Information
CHP 834 Unrelated and Partially Matched Related Donor Peripheral Stem Cell Transplantation With The CliniMACS Device for T and B Cell Depletion
Inclusion Criteria:
- All races are eligible
- Malignant diseases: Leukemias and Lymphomas
- Non-malignant diseases: Severe Aplastic Anemia, immunodeficiencies
Exclusion Criteria:
- Lansky or Karnofsky > 70
- Echo > 27% shortening fraction
- renal function:serum creatinine < 1.5 x for normal age
- no active untreated infection
- DLCO > 50% of predicted value
- Hepatic: AST and ALT < 3x upper limit of normal; bilirubin < 2.0.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
To measure the incidence and quality of engraftment
Outcome Time Frame:
Weekly for first 100 days, 6 months and 1 year
Safety Issue:
Yes
Principal Investigator
Julie A Talano, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Medical College of Wisconsin
Authority:
United States: Food and Drug Administration
Study ID:
CHOP 07/216
NCT ID:
NCT01071226
Start Date:
May 2008
Completion Date:
May 2019
Related Keywords:
- Malignant Diseases (ie, Leukemia, MDS, Lymphoma)
- Non-malignant Diseases (ie, Bone Marrow Failure Syndromes)
- Malignant and non-malignant diseases
- Hematopoietic stem cell transplant
- Peripheral blood progenitor cell transplant
- CliniMACS device
- T cell depletion
- Leukemia
- Lymphoma
- Pancytopenia
- Hemoglobinuria, Paroxysmal
Name | Location |
Children's Hospital of Wisconsin |
Milwaukee, Wisconsin 53201 |